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Abstract
Background: Fractional exhaled nitric oxide (FENO), a non-invasive marker of eosinophilic airway inflammation, is
increasingly used for diagnostic and therapeutic decisions in adult and paediatric asthma. Standardized guidelines for the
measurement of FENO recommend performing FENO measurements before rather than after bronchial provocation tests.
Objective: To investigate whether FENO levels decrease after a Mannitol dry powder (MDP) challenge in a clinical setting,
and whether the extent of the decrease is influenced by number of MDP manoeuvres, baseline FENO, atopy and doctor
diagnosed asthma.
Methods: Children aged 6–16 years, referred for possible reactive airway disease to a respiratory outpatient clinic,
performed an MDP challenge (AridolH, Pharmaxis, Australia). FENO was measured in doublets immediately before and after
the challenge test using the portable NIOX MINOH device (Aerocrine, Stockholm, Sweden). We analysed the data using
Kruskal-Wallis rank tests, Wilcoxon signed rank tests and multivariable linear regressions.
Results: One hundred and seven children completed both tests (mean6SD age 11.562.8 years). Overall, median
(interquartile range) FENO decreased slightly by 22.5 ppb (27.0, 20.5), from 18.5 ppb (10.5, 45.5) before the MDP
challenge to 16.5 ppb thereafter (8.5, 40.5; p,0.001). In all participants, the change in FENO was smaller than one standard
deviation of the baseline mean. The % fall in FENO was smaller in children with less MDP manoeuvres (e.g. higher bronchial
responsiveness; p = 0.08) but was not influenced by levels of baseline FENO (p= 0.68), atopy (p = 0.84) or doctor diagnosed
asthma (p = 0.93).
Conclusion: MDP challenge test influences FENO values but differences are small and clinically barely relevant.
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Introduction
Asthma is the most common chronic disease of childhood, and
its diagnosis remains clinical [1]. A diagnosis of asthma in children
is usually based on history of a characteristic pattern of episodic
respiratory symptoms and signs in the absence of an alternative
explanation of them. In children, as in adults, tests of airflow
obstruction, airway responsiveness and airway inflammation may
provide support for a diagnosis of asthma [1]. The frequent finding
of exercise-related airway narrowing in many children with
asthma has been used as a diagnostic tool for years, especially
when the diagnosis of asthma is uncertain [2]. Testing for exercise
induced bronchoconstriction is not very sensitive, but highly
specific for the diagnosis of pediatric asthma compared to direct
bronchial provocation tests using methacholine [3].
Mannitol dry powder (MDP) is a new indirect bronchial
provocation test, consisting of a hyperosmolar challenge compa-
rable to hypertonic saline [4,5]. In children, a MDP challenge is
easier, quicker to perform and better tolerated than a challenge
test with hypertonic saline or methacholine, and it shows
comparable accuracy for diagnosing asthma as exercise testing
[6–9]. For these reasons, it is likely to become one of the standard
bronchial challenge tests in clinical practice and research [10].
Fractional exhaled nitric oxide (FENO), a non-invasive marker
of eosinophilic airway inflammation, is increasingly used for
diagnostic and therapeutic decisions in adult and paediatric
asthma [11]. Standardized guidelines for the measurement of
FENO, published by the European Respiratory Society (ERS) and
the American Thoracic Society (ATS) [12], recommend to
perform FENO measurements before rather than after exercise
testing, because both spirometry and exercise affect FENO levels
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in children, particularly those with asthma [13,14]. To plan the
sequence of different tests for single children, it is important to
know whether FENO levels are affected by a MDP challenge,
similarly as by exercise tests.
The aim of this study was therefore to determine whether
FENO levels decrease after a MDP challenge in a clinical setting.
In addition, we assessed whether the extent of this decrease is
affected by: baseline FENO, severity of bronchial hyperrespon-
siveness (BHR, which is inversely proportional to the number of
MDP manoeuvres), atopy or a diagnosis of asthma.
Methods
Ethics Statement
All parents and children gave informed consent for the study.
The local ethics committee and the Swiss agency for the
authorisation and surveillance of therapeutic products (Swissme-
dic) approved the study.
Subjects and Study Design
We studied 107 white children (Caucasian Europeans) aged 6 to
16 years, who had been referred for possible reactive airway
disease to respiratory outpatient clinics in two tertiary children’s
hospitals in Switzerland (St.Gallen, Basel). Details of the study
have been published elsewhere [6]. Exclusion criteria were other
respiratory diseases (e.g. cystic fibrosis, primary ciliary dyskinesia)
and a respiratory tract infection during the preceding four weeks.
Fractional Exhaled NO
We measured FENO in doublets immediately before and after
the MDP challenge using the portable multi-gas analyzer (NIOX
MINOH, Aerocrine, Sweden), in accordance with published
guidelines [12] and previous studies using this device [15,16].
The portable analyzer ensures a constant expiratory flow of
5065 ml/s, has an accuracy of 610% with a minimum of
65 ppb. FENO measurements from this portable analyzer
correlate well with those obtained by chemiluminiscence detectors
[16].
Mannitol Dry Powder Challenge
The MDP challenge (AridolH, Pharmaxis, New South Wales,
Australia) was performed as described previously [5,7]. In brief,
subjects were asked to inhale the contents of a MDP capsule
through the delivery device (OsmohalerH). Doses were increased
step-wise (0, 5, 10, 20, 40, 80, 160, 160, 160 mg) until there was
either a $15% fall of forced expiratory volume in 1 second (FEV1)
compared to baseline, or a 10% fall in FEV1 between two doses.
After each dose, children were instructed to perform a 5-second
breath-hold, and then spirometry was performed in duplicates one
minute later, and the higher FEV1 was recorded. The results of the
MDP challenge were reported as a percent decrease of FEV1 from
baseline (FEV1 value measured after the 0-mg capsule), and the
provocative dose inducing a 15% drop of FEV1 (PD15) was
calculated. At the end of the challenge, a short-acting beta2-
agonist was given to reverse bronchoconstriction. A negative MDP
challenge, defined as no significant fall in FEV1 after a cumulative
dose of 635 mg, included eleven FEV1 manoeuvres in doublets.
BHR severity is defined as mild (155–635 mg, 8–10 manoeuvres),
moderate (35–155 mg, 5–7 manoeuvres) and severe (,35 mg, #4
manoeuvres).
Clinical Assessment
The responsible paediatric respiratory physicians made a
diagnosis (asthma, or alternative diagnoses) for every child after
the first visit, taking into consideration medical history, clinical
examination and all conventional test results (including broncho-
dilator response) before MDP challenge and FENO measurement
were performed.
Skin Prick Test
We performed skin prick tests (SPT) using birch, grass,
mugwort, alternaria, cat, house dust mites (D. pteronyssinus) and
positive and negative controls, considering a wheal of .3 mm as
positive. These allergens cover 95% of inhaled allergies in
Switzerland [17]. Atopy is defined as mild (1 to 2 positive SPT)
and moderate ($3 positive SPT).
Statistics
We analysed the data with STATA, version 11.2 (Stata
Corporation, Austin, Texas). Because FENO levels were not
normally distributed, we used non-parametric tests: the Kruskal-
Wallis rank test to compare FENO levels between groups and the
Wilcoxon signed rank test to compare FENO levels before and
after MDP challenge. We assessed the association between %
difference in FENO and levels of baseline FENO, doctor
diagnosed asthma, atopy and BHR severity, using linear
regressions.
Table 1. Patients characteristics (N = 107).
Characteristics N (%)
Patients, No 107
Anthropometric data
Male gender 66 (62%)
Age, yr * 12 (9–14; 6–17)
Height, cm * 147 (132–164; 115–182)
Weight, kg * 38 (29–54; 20–84)
Clinical features
Doctor diagnosis of asthma 64 (60%)
More than 4 attacks of wheeze 38 (36%)
Use of inhaled corticosteroids 14 (13%)
Atopy
None (negative SPT) 18 (17%)
Mild (1 to 2 positive SPT) 39 (36%)
Moderate ($3 positive SPT) 50 (47%)
Spirometry (at baseline)*
FVC, % predicted 99 (90–108; 65–128)
FEV1, % predicted 97 (88–104; 69–128)
FEV1/FVC 83 (76–88; 61–99)
MEF50, % predicted 75 (61–91; 29–126)
BHR severity (MDP challenge){
Normal (.635 mg, 11 manoeuvres) 76 (71%)
Mild (155–635 mg, 8–10 manoeuvres) 16 (15%)
Moderate to severe (,155 mg, #7 manoeuvres) 15 (14%)
Abbreviations: SPT, skin prick test; FVC, forced volume capacity; FEV1, forced
expiratory volume in 1 sec; MEF50, maximal expiratory flow at 50%; BHR,
bronchial hyperresponsiveness; MDP, mannitol dry powder.
*Results reported as median (interquartile range; range).
{BHR reported as MDP challenge results (provocative dose (in mg) inducing a
15% drop of FEV1 (PD15)). BHR severity is directly correlated with No of MDP
manoeuvres.
doi:10.1371/journal.pone.0054521.t001
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Results
One hundred and seven children completed both tests
(mean6SD age 11.562.8 years). Eighty nine children (83%) were
sensitized to at least one allergen and 71 (66%) to two or more, 64
(60%) were diagnosed by the clinician as having asthma, and 14
(13%) were on inhaled corticosteroids (Table 1). The MDP
challenge was positive (BHR severity mild to severe) in 31 children
(29%). Median (interquartile range IQR) FENO levels at baseline
were higher in children diagnosed with asthma (26.0 (12.5,63.0) vs.
14.5 (8.0,22.5)), in atopic children (moderate 21.3 (12.5,56.5), mild
22.0 (12.5,49.0), none 8.0 (5.5,14.5)), and in those with a positive
MDP challenge test (moderate to severe 65.0 (40.5,122.5), mild
42.5 (25.0,71.3), normal 14.0 (9.3,22.3); all p#0.001).
Overall, median (IQR) FENO decreased by 22.5 ppb (27.0,
20.5), from 18.5 ppb (10.5,45.5) before the MDP challenge to
16.5 ppb thereafter (8.5,40.5; p,0.001, Table 2). This change
corresponds to a % difference of 211.2% (95% confidence
interval 215.2, 27.1; Figure 1). In 81 children (76%) FENO
decreased after the MDP challenge (median difference (IQR;
range)23.5 ppb (28.5,22.5;227.5,20.5)), in 18 (17%) children
FENO levels increased (median difference 2.0 ppb (1.0,6.0;
0.5,9.5)) and in 8 (7%) they remained identical. In none of the
children the change in FENO was larger than one standard
deviation of the baseline mean. There was no association between
% difference of FENO after MDP challenge and levels of baseline
FENO (p= 0.68), doctor diagnosed asthma (p= 0.93) or presence
Figure 1. % difference of FENO after MDP challenge by baseline FENO, asthma, atopy and BHR severity. Abbreviations: FENO, fractional
exhaled nitric oxide; MDP, mannitol dry powder; BHR, bronchial hyperresponsiveness; SPT, skin prick test. Baseline FENO defined as tertiles (low levels:
,13 ppb; medium levels: 13 ppb–30 ppb; high levels: .30 ppb). Atopy defined as none (negative SPT), mild (1 to 2 positive SPT), moderate ($3
positive SPT). BHR reported as MDP challenge results (provocative dose (in mg) inducing a 15% drop of FEV1 (PD15)) and defined as normal
(.635 mg, 11 manoeuvres), mild (155–635 mg, 8–10 manoeuvres), moderate to severe (,155 mg, #7 manoeuvres).
doi:10.1371/journal.pone.0054521.g001
Table 2. Levels of FENO at baseline and after mannitol dry powder challenge.
FENO at baseline FENO after MDP challenge
N Median IQR Median IQR p-value{
All children 107 18.5 10.5–45.5 16.5 8.5–40.5 ,0.001
Doctor diagnosis of asthma
No 43 14.5 8.0–22.5 12.0 6.5–20.0 ,0.001
Yes 64 26.0 12.5–63.0 23.3 10.3–56.8 ,0.001
Atopy
No (negative SPT) 18 8.0 5.5–14.5 6.8 5.0–12.0 0.006
Mild (1 to 2 positive SPT) 39 22.0 12.5–49.0 19.0 10.5–43.5 ,0.001
Moderate ($3 positive SPT) 50 21.3 12.5–56.5 21.3 9.5–46.5 ,0.001
BHR severity (MDP challenge)*
Normal (.635 mg, 11 manoeuvres) 76 14.0 9.3–22.3 12.3 7.3–20.8 ,0.001
Mild (155–635 mg, 8–10 manoeuvres) 16 42.5 25.0–71.3 35.5 17.0–67.8 0.005
Moderate to severe (,155 mg, #7 manoeuvres) 15 65.0 40.5–122.5 64.5 46.5–102.5 0.079
Abbreviations: SPT, skin prick test; BHR, bronchial hyperresponsiveness; MDP, mannitol dry powder; FENO, fractional exhaled nitric oxide; IQR, interquartile range.
*BHR reported as MDP challenge results (provocative dose (in mg) inducing a 15% drop of FEV1 (PD15)). BHR severity is directly correlated with No of MDP manoeuvres.
{Non-parametric test, matched group =Wilcoxon signed rank test comparing medians of FENO at baseline and after MDP challenge.
doi:10.1371/journal.pone.0054521.t002
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of atopy (p= 0.84; Figure 1). However, the difference tended to
be smaller in children who had moderate to severe BHR
compared to those with normal BHR (p= 0.08; Figure 1).
Discussion
This study showed that FENO levels are indeed slightly reduced
after a MDP challenge, compared to baseline. The differences,
although statistically significant, were however small and unlikely
to affect clinical decisions relating to diagnosis or treatment.
Results were unaffected by baseline FENO levels, the presence
of atopy or doctor diagnosed asthma. However, the decrease was
larger in children with normal MDP challenge who had performed
more MDP manoeuvres (11) compared to those with moderate to
severe BHR with less MDP manoeuvres (#7). This suggests that
the increased ventilation associated with repeated MDP manoeu-
vres and associated spirometries might have caused the decrease.
The median decrease (22.5 ppb, IQR 27.0, 20.5) was compa-
rable or a bit larger than the decrease reported for spirometry
alone [3,4], but smaller than the decrease reported for exercise
tests (25 ppb, from 223.5 ppb to 218.5 ppb) [13].
To our knowledge, this is the first study comparing FENO levels
before and after MDP challenges. It includes a large number of
children (107) and the clinical setting guarantees that results are
representative for patients referred to respiratory outpatient clinics
for potential reactive airways disease. Because most children were
atopic and the majority diagnosed with asthma, results should not
be extrapolated to healthy non-atopic children.
In conclusion, this study provides further support for the
recommendation that FENO measurements in children, as a rule,
should preferably be performed before spirometry and before
bronchial provocation testing. This is particularly true for
research. However, as the differences are small and clinically
barely relevant, FENO measurements can still be interpreted even
if performed after a MDP challenge test.
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